← Eichor
Condition: Locally Advanced Solid Tumor Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Locally Advanced Solid Tumor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of ESG406 in Adults With Solid Tumors
Phase 1 · 3 location(s) · Shanghai Escugen Biotechnology Co., Ltd · NCT06979674A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06475300HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT07296341A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors
Phase 1 · 7 location(s) · Bliss Biopharmaceutical (Hangzhou) Co., Ltd · NCT05217693A Study of ASP1002 in Adults for Treatment of Solid Tumors
Phase 1 · 15 location(s) · Astellas Pharma Global Development, Inc. · NCT05719558A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Meth
Phase N/A · 1 location(s) · Centro di Riferimento Oncologico - Aviano · NCT06028724Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT05059678Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06493864Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Phase 1 · 36 location(s) · Inhibrx Biosciences, Inc · NCT03715933RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
Phase 1 · 1 location(s) · RemeGen Co., Ltd. · NCT05940896SB17170 Phase 1 Clinical Trial in Solid Tumors
Phase 1 · 3 location(s) · SPARK Biopharma · NCT05522868A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
Phase 2 · 4 location(s) · ImmuneOncia Therapeutics Inc. · NCT06365840BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation
Phase 1 · 1 location(s) · Changchun GeneScience Pharmaceutical Co., Ltd. · NCT06908434A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or
Phase 1/Phase 2 · 1 location(s) · AP Biosciences Inc. · NCT05473156Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT03907475A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
Phase 1 · 3 location(s) · Proviva Therapeutics, Inc. · NCT06190886PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostat
Phase 2/Phase 3 · 1 location(s) · Affidea Nu-med Center of Oncological DIagnostics and Therapy · NCT07426055A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
Phase 1/Phase 2 · 8 location(s) · Yuhan Corporation · NCT06616766A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07056556A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1/Phase 2 · 68 location(s) · Turning Point Therapeutics, Inc. · NCT04094610A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
Phase 1/Phase 2 · 2 location(s) · Spago Nanomedical AB · NCT06184035A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Phase 1 · 4 location(s) · Chugai Pharmaceutical · NCT05907980A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malign
Phase 1 · 1 location(s) · GigaGen, Inc. · NCT06258304Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04879121A Study of ASP3082 in Adults With Advanced Solid Tumors
Phase 1 · 62 location(s) · Astellas Pharma Inc · NCT05382559A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid M
Phase 1 · 2 location(s) · Zelluna Immunotherapy AS · NCT07613723Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion
Phase 1 · 3 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT06968572A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors
Phase 1 · 3 location(s) · Guangzhou Virotech Pharmaceutical Co., Ltd. · NCT06368921
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.